Observation of rituximab as initial treatment in patients with minimal change disease- a retrospective study
The use of RTX can effectively induce and maintain remission in MCD patients, demonstrating efficacy comparable to those treated with GC. Furthermore, the safety profile is favorable, making it a viable alternative to GC therapy. This provides a reliable initial treatment option for patients with MCD, particularly for pediatric patients.
Authors
- Zong Li (ORCID: https://orcid.org/0000-0002-7478-3402)
- Ke Zhao (ORCID: https://orcid.org/0000-0001-6097-9431)
- Xiaoyan Xiao (ORCID: https://orcid.org/0000-0002-6320-4807)
- Fengzhang Lv
- Hua Liang (ORCID: https://orcid.org/0000-0003-3170-6922)
- Sha Wang (ORCID: https://orcid.org/0000-0003-4661-9581)
- Xiangdong Yang
- Luyao Li (ORCID: https://orcid.org/0000-0003-1397-5045)
- Miaomiao Cheng
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1528996
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shandong University
- National Natural Science Foundation of China